Fevzi Ozkaynak, MD

Professor of Pediatrics
Pediatric Hematology/Oncology, New York Medical College
Director, Pediatric Blood and Marrow Transplant Program
Maria Fareri Children’s Hospital at Westchester Medical Center

University of Hacettepe, School of Medicine, Ankara (1978)

Residency in Pediatrics, Hacettepe Children’s Hospital, Ankara (1978-1982)
Residency in Pediatrics, Childrens Hospital of Los Angeles (1989-1991)
Fellowship in Peds. Hem/Onc/BMT, Childrens Hospital of LA (1986-1989)

2009-2010: Interim Chief, Peds Hem/Onc, NYMC, Dept. of Pediatrics
2003-Present: Professor of Pediatrics, New York Medical College
1999-2003: Associate Professor of Pediatrics, New York Medical College
1994-1999: Assistant Professor of Pediatrics, New York Medical College
1992-1994: Asst. Professor of Pediatrics, University of Southern California
1994-Present: Director, Peds. Blood & Bone Marrow Transplantation, Maria Fareri Children’s Hospital at Westchester Medical Center
1990-1993: Assistant Clinical Director, Autologous Bone Marrow Transplantation Program, Division of Hematology/Oncology, Childrens Hospital of Los Angeles
1993-1994: Director, Peripheral Stem Cell Program, Childrens Hospital of Los Angeles

1994-1999: Chairperson, Childrens Cancer Group Protocol #0935:
A Phase I Study of Chimeric Human/Murine AntiGD2 Monoclonal Antibody (ch14.18) with GM-CSF in Children with Neuroblastoma.

1998-Present: Vice-Chairperson, Childrens Oncology Group #ANBL0032:
Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue.

1997-2005: Chairperson, Childrens Oncology Group Protocol # AS973:
A Randomized Comparison Between Antibiotics Alone and Antibiotics Plus G-CSF in Pediatric Patients with Chemotherapy Induced Febrile Neutropenia.

2000-2007: Chairperson, Pediatric Blood and Marrow Consortium, A Phase I Trial of Amifostine with L-PAM, Carboplatin, Etoposide with Escalating Doses of Cyclophosphamide with Autologous PBSC in Children with Pediatric Solid Tumors

2009-Present: Chairperson, Childrens Oncology Group #ANBL0931:
A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) with GM-CSF, IL-2 AND Isotretinoin in Hgh-Risk Neuroblastoma Patients Following Myeloablative Therapy.

Childrens Hospital LA, LA, CA, Attending, 7/1991 – 6/1994
Maria Fareri Childrens Hospital/Westchester Medical Center, Valhalla, NY, Attending, 7/1994-Present
Vassar Medical Center, Poughkeepsie, NY : Consultant, 2/1996-Present
Danbury Hospital, Danbury, CT: Consultant, 7/1997-Present
Our Lady of Mercy/Montefiore North, Bronx, NY: Consultant, 1/1999-Present